Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

8/12/24 9:40:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SLRN alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 ACELYRIN INC COMMON STOCK Cusip #00445A100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00445A100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,882,214 Item 6: 0 Item 7: 3,884,690 Item 8: 0 Item 9: 3,884,690 Item 11: 3.922% Item 12: HC Cusip #00445A100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,884,690 Item 8: 0 Item 9: 3,884,690 Item 11: 3.922% Item 12: IN Item 1(a). Name of Issuer: ACELYRIN INC Item 1(b). Address of Issuer's Principal Executive Offices: 4149 LIBERTY CANYON RD AGOURA HILLS, CA 91301 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 00445A100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,884,690 (b) Percent of Class: 3.922% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,884,690 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ACELYRIN INC. No one other person's interest in the COMMON STOCK of ACELYRIN INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. August 9, 2024 Date /s/ Richard Bourgelas Signature Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on August 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ACELYRIN INC at July 31, 2024. FMR LLC By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Get the next $SLRN alert in real time by email

Recent Analyst Ratings for

$SLRN

Date	Price Target	Rating	Analyst
8/14/2024	$18.00 → $6.00	Buy → Neutral	H.C. Wainwright
7/8/2024	$13.00	Equal Weight → Overweight	Wells Fargo
12/13/2023	$11.00	Equal Weight	Wells Fargo
12/8/2023	$8.00	Neutral	Citigroup
9/13/2023	$19.00	Overweight → Equal-Weight	Morgan Stanley
9/5/2023	$44.00	Buy	H.C. Wainwright
5/30/2023		Overweight	Morgan Stanley
5/30/2023	$31.00	Buy	Jefferies

More analyst ratings

Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

Chat with this insight

Recent Analyst Ratings for $SLRN

$SLRN SEC Filings

SEC Form 10-Q filed by ACELYRIN INC.

ACELYRIN INC. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

ACELYRIN INC. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$SLRN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by ACELYRIN INC.

Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

SEC Form SC 13G filed by ACELYRIN INC.

$SLRN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ACELYRIN downgraded by H.C. Wainwright with a new price target

ACELYRIN upgraded by Wells Fargo with a new price target

Wells Fargo initiated coverage on ACELYRIN with a new price target

$SLRN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CFO and CBO Labrucherie Gil M

Director Becker Daniel J. sold $7 worth of shares (1 units at $6.86), decreasing direct ownership by 0.03% to 2,999 units (SEC Form 4)

SEC Form 4 filed by Director Seidenberg Beth C

$SLRN Press Releases

Fastest customizable press release news feed in the world

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

$SLRN Leadership Updates

Live Leadership Updates

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

$SLRN Market Insights

Live Market Insights

Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session

ACELYRIN shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and maintained its $13 price target.

Wells Fargo Upgrades Acelyrin to Overweight, Maintains Price Target to $13

$SLRN Financials

Live finance-specific insights

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

Recent Analyst Ratings for
$SLRN

$SLRN
SEC Filings

$SLRN
Large Ownership Changes

$SLRN
Analyst Ratings

$SLRN
Insider Trading

$SLRN
Press Releases

$SLRN
Leadership Updates

$SLRN
Market Insights

$SLRN
Financials